Table 1 Baseline characteristics
Hospitalisation Cohort | Frailty Cohort | Polypharmacy Cohort | Overlap group | Background population | |
|---|---|---|---|---|---|
n | 90,597 | 110,225 | 116,076 | 28,259 | 277,332 |
Hospitalisation Cohort | 90,597 (100.0%) | 40,726 (36.9%) | 42,815 (36.9%) | 28,259 (100.0%) | 0 (0) |
Frailty Cohort | 40,726 (45.0%) | 110,225 (100.0%) | 63,577 (54.8%) | 28,259 (100.0%) | 0 (0) |
Polypharmacy Cohort | 42,815 (47.3%) | 63,577 (57.7%) | 116,076 (100.0%) | 28,259 (100.0%) | 0 (0) |
Gender = Male | 39,201 (43.3%) | 45,272 (41.1%) | 45,578 (39.3%) | 11,470 (40.6%) | 129,406 (46.7%) |
Age (mean (SD)) | 78.16 (7.76) | 78.74 (7.41) | 78.19 (7.38) | 79.66 (7.41) | 74.73 (6.97) |
Socio-economic statusa | |||||
1 (least deprived) | 20,559 (22.7%) | 24,226 (22.0%) | 25,520 (22.0%) | 5632 (19.9%) | 78,067 (28.1%) |
2 | 21,641 (23.9%) | 25,823 (23.4%) | 26,496 (22.8%) | 6340 (22.4%) | 72,208 (26.0%) |
3 | 19,291 (21.3%) | 23,633 (21.4%) | 24,482 (21.1%) | 6003 (21.2%) | 57,973 (20.9%) |
4 | 16,921 (18.7%) | 21,331 (19.4%) | 22,730 (19.6%) | 5760 (20.4%) | 44,379 (16.0%) |
5 (most deprived) | 12,112 (13.4%) | 15,134 (13.7%) | 16,744 (14.4%) | 4501 (15.9%) | 24,525 (8.8%) |
BMI (mean (SD)) | 27.10 (5.55) | 27.95 (5.78) | 28.31 (5.86) | 27.59 (5.97) | 26.73 (4.66) |
Charlson Comorbidity Indexb (mean (SD)) | 0.37 (0.92) | 0.51 (1.02) | 0.38 (0.91) | 0.64 (1.15) | 0.08 (0.42) |
General Practitioner visitsb (median IQR]) | 12 [7,19] | 14 [9,21] | 15 [10,22] | 19 [13,27] | 5 [2,8] |
eFIb (median [IQR]) | 2 [1,3] | 3 [3,4] | 3 [2,4] | 4 [3,5] | 1 [0, 1] |
Unplanned hospital admissionsb (median [IQR]) | 1 [1,2] | 0 [0, 1] | 0 [0, 1] | 1 [1,2] | 0 [0, 0] |
Number of different drugsb (median [IQR]) | 9 [6,13] | 10 [8,14] | 13 [11,15] | 14 [12,18] | 4 [1,6] |